Alice B. Gottlieb, MD, PhD

Gottlieb reviews her lecture from the Society for Investigative Dermatology Annual Meeting.

Alice Gottlieb, MD, PhD, put a spotlight on recent studies and the current psoriasis treatment armamentarium for dermatology clinicians to consider.

Drs Mark G. Lebwohl and Alice B. Gottlieb discuss future expectations in the treatment of plaque psoriasis.

Mark G. Lebwohl, MD, and Alice B. Gottlieb, MD, PhD, discuss gaps in care for the treatment of plaque psoriasis.

Expert dermatologists discuss the risk of candidiasis with IL-17 inhibitors when managing plaque psoriasis and how to manage candidiasis.

Drs Mark G. Lebwohl and Alice B. Gottlieb discuss the novel mechanism of bimekizumab and how it can change the treatment landscape for plaque psoriasis.

Mark G. Lebwohl, MD, and Alice B. Gottlieb, MD, PhD, discuss the durability of IL-17 inhibitors in managing plaque psoriasis.

Expert dermatologists discuss how to select treatment for plaque psoriasis while taking comorbidities into consideration.

Drs Mark G. Lebwohl and Alice B. Gottlieb discuss how to select treatment for plaque psoriasis based on mechanism of action.

Mark G. Lebwohl, MD, and Alice B. Gottlieb, MD, PhD, discuss pathogenesis of plaque psoriasis and new emerging targets.

Psoriasis is a chronic inflammatory disease characterized by well-demarcated red, raised, scaly lesions on any part of the body. The disease often severely impacts patients' mental and physical functioning and quality of life. Signs and symptoms may vary from mild to generalized cutaneous involvement, with or without associated joint disease.